PREGNANCY OUTCOME IN FEMALE PATIENTS WITH CHRONIC MYELOID LEUKEMIA WORLDWIDE: ANALYSIS OF 305 CASES OF THE EUROPEAN LEUKEMIA NET REGISTRY
Author(s): ,
Ekaterina Chelysheva
Affiliations:
National Research Center for Hematology,Moscow,Russian Federation
,
Anna Turkina
Affiliations:
National Research Center for Hematology,Moscow,Russian Federation
,
Delphine Rea
Affiliations:
Adult Hematology department,Hospital Saint-Lois,Paris,France
,
Philippe Rousselot
Affiliations:
Hematology Oncology Department,Versailles University,Versailles,France
,
Frank Emmanuel Nicolini
Affiliations:
Centre Hospitalier Universitaire de Lyon,Lyon,France
,
Malgorzata Monika Trawinska
Affiliations:
Hematology unit,S. Eugenio Hospital, Tor Vergata University,Rome,Italy
,
Atelda Romano
Affiliations:
IRCCS- Istituto Nazionale Tumori, Regina Elena,Rome,Italy
,
Michele Malagola
Affiliations:
Division of Hematology and Stem Cell Transplantation,Brescia University,Brescia,Italy
,
Domenica Cangemi
Affiliations:
Ospedale Spaziani,Frosinone,Italy
,
Irina Dyagil
Affiliations:
National Science Center of Radiation Medicine of National Medical Science Academy of Ukraine,Kyiv,Ukraine
,
Konstantin Kotlyarchuk
Affiliations:
SI 'Institute of Blood Pathology and Transfusion Medicine UAMS,Lviv,Ukraine
,
Khamida Kazakbaeva
Affiliations:
Research Institute of Hematology and Blood Transfusion MOH of Uzbekistan,Tashkent,Uzbekistan
,
Sukhrob Saliev
Affiliations:
Research Institute of Hematology and Blood Transfusion MOH of Uzbekistan,Tashkent,Uzbekistan
,
Carolina Pavlovsky
Affiliations:
Department of Hematology Oncology,Fundaleu Hospitalization & Clinical Research Center,Buenos Aires,Argentina
,
Beatriz Moiraghi
Affiliations:
Hospital General De Agudos J. M. Ramos Mejia,Buenos Aires,Argentina
,
Dong-Wook Kim
Affiliations:
Department of Hematology,Seoul St. Mary's Hospital The Catholic University of Korea,Seoul,Korea, Republic Of
,
Hana Klamova
Affiliations:
Institute of Hematology and Blood Transfusion,Praga,Czech Republic
,
Mohamed Yassin
Affiliations:
Department of Hematology and Medical Oncology,National Center for Cancer Care and Research, Hamad Medical Corporation,Doha,Qatar
,
Karen Meliktesyan
Affiliations:
Hematology Center named after prof. R.O.Eolyan of Health Ministry of Armenia,Yerevan,Armenia
,
Georgi Mikhailov
Affiliations:
National Specialized Hospital for Active Treatment of Hematological Diseases,Sofia,Bulgaria
,
Penka Ganeva
Affiliations:
National Specialized Hospital for Active Treatment of Hematological Diseases,Sofia,Bulgaria
,
Santiago Osorio
Affiliations:
Hematology Department,Hospital General Universitario Gregorio Marañón,Madrid,Spain
,
Michael Mauro
Affiliations:
Memorial Sloan Kettering Cancer Center,New York,United States
,
Evgenya Polushkina
Affiliations:
FSBI Scientific Center of Obstetrics, Gynecology and Perinatology of Healthcare Ministry named after V.I. Kulakov,Moscow,Russian Federation
,
Roman Shmakov
Affiliations:
FSBI Scientific Center of Obstetrics, Gynecology and Perinatology of Healthcare Ministry named after V.I. Kulakov,Moscow,Russian Federation
,
Julia Chabaeva
Affiliations:
National Research Center for Hematology,Moscow,Russian Federation
,
Sergey Kulikov
Affiliations:
National Research Center for Hematology,Moscow,Russian Federation
Elisabetta Abruzzese
Affiliations:
Hematology Unit,S. Eugenio Hospital, Tor Vergata University,Rome,Italy
EHA Library. Chelysheva E. Jun 15, 2019; 267464; S881
Dr. Ekaterina Chelysheva
Dr. Ekaterina Chelysheva
Contributions
×
Abstract
This abstract is embargoed until Friday, June 14, 08:30 local time.

Abstract: S881

Type: Oral Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 16:00 - 16:15

Location: Forum Hall

Background
Family planning is important in patients (pts) with chronic myeloid leukemia (CML) who can have a near normal lifespan in tyrosine kinase inhibitors (TKI) era. Management of CML on conceptions and pregnancies is not defined as cases are rare and data are scarce. To investigate this issue a multicenter retrospective and prospective observational study of conception/pregnancy in CML pts was initiated within the European LeukemiaNet (ELN) from February 2014 till present. All ELN centers and participants from other countries were invited and received the study’s protocol which was adopted in agreement with specific national laws.

Aims
The main goal was to describe CML pts in terms of pregnancy/conceptions management and outcome. Secondary goals included demographics, characteristics of CML, management during pregnancy, pregnancy outcomes and characteristics of children.

Methods

Adult pts aged >18 years with Ph+ positive CML and pregnancy were included after signing a written informed consent. Data were collected either in the coordinating centers in Moscow (Russia) and Rome (Italy) followed by the analyses of the entire data set. A total 305 pregnancy cases in 234 CML female pts from 15 centers of 13 countries worldwide were analyzed (Table 1).

Results

Chronic phase at diagnosis was in 217/221(98%) pts. In 50 (21%) pts CML was diagnosed during pregnancy, while 184 (67%) got pregnant after diagnosis. Median (Me) time from CML diagnosis to pregnancy was 59 months (range 1-203).

The outcomes of 305 pregnancies were as follows: labor 234 (77%), induced abortion 42 (14%), spontaneous abortion 21 (7%) and ongoing pregnancy or unknown outcome 8 (2%). Labor at full term was in 141 (75%) of 187 cases fully reported (Table 2).

Molecular response (MR) evaluations at the start of pregnancy were recorded in 249/305 cases. Deep MR (DMR or BCR-ABL<0,01% IS), major MR (MMR or BCR-ABL<0,1%> >0,01% IS), MR2 (BCR-ABL>0,1%> <1% IS) and no MR2 (BCR-ABL>1% IS) was observed in 80 (32%), 31 (12%), 32 (13%) and 106 (43%) cases respectively.

In 182 (71%) of 257 pregnancies with known data pts conceived while on TKI: 77% under imatinib (IM) and 23% TKI 2nd/3rd generation. TKIs were usually stopped early in 1st trimester (4-5 week of gestation) when the pregnancy was discovered.

In 82 pregnancies pts were treated during 2nd-3rd trimester, after placental formation, until labor with IM: 33 (40%) of cases), nilotinib (NIL): 8 (9%), interferon (IFN): 23 (28%, 1 PEG-IFN), hydroxyurea: 6 (7%).  IM was used throughout pregnancy in 13 (16%). One case of leukaferesis was recorded.

The number of born children in 226 fully reported labors was 233 (including twins). Congenital abnormalities were recorded in 4 (1,7%) cases as follows: polydactyly (1), hypospadias (1) and non-closed foramen ovale of interatrial septum (2). None of the abnormalities were severe or life threatening, relationship to TKI use was considered unlikely by physicians. Low birth weight was recorded in 13 children with IM or NIL exposure at late pregnancy. The follow-up of all children was uneventful, with Me age at follow-up of 5 years (range 2 months-17 years).

Conclusion
Most pregnancies in CML female pts resulted in normal childbirth with no increased rate of birth abnormalities in spite of TKI use at conception even if treatments were mostly early stopped at implant (4-5 weeks). Different therapies were used during pregnancy when needed. The results in terms of conception/pregnancy may be valuable for the development of CML treatment schemes particularly considering the variety of disease status.

Session topic: 8. Chronic myeloid leukemia - Clinical

Keyword(s): Chronic myeloid leukemia, Interferon, Pregnancy, Tyrosine kinase inhibitor

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies